Emerflu

The A/H5N1 inactivated split virion pandemic influenza vaccine, known by the brand name **Emerflu**, is a monovalent, inactivated, split-virion biological vaccine developed by Sanofi Pasteur. It is designed for the prevention of pandemic influenza caused by the H5N1 strain. The vaccine's active ingredient is the haemagglutinin (HA) antigen derived from the influenza A/Vietnam/1194/2004 NIBRG-14 (H5N1) strain. The primary studied formulation contains 30 µg of HA adjuvanted with aluminium hydroxide (Al(OH)3) to enhance immunogenicity. Administered via intramuscular injection, the vaccine targets the H5 haemagglutinin surface protein of the influenza A/H5N1 virus, stimulating a humoral and predominantly Th2-skewed cellular immune response. Although clinical trials demonstrated that the vaccine was well tolerated and immunogenic across various age groups, including children, Sanofi Pasteur withdrew its marketing authorisation application from the European Medicines Agency in December 2010.

Brand names

Emerflu

Other names

A/H5N1 inactivated split virion pandemic influenza vaccineH5N1 pandemic influenza vaccineH-5N1 pandemic influenza vaccineH 5N1 pandemic influenza vaccineA/Vietnam/1194/2004 NIBRG-14 (H5N1) vaccineSanofi H5N1 vaccine